Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries
Boston Scientific shares rose 2.8% to $77.64 in Thursday’s after-hours trading, rebounding after a record 17% plunge Wednesday on weak Q4 electrophysiology and Watchman sales. Citi and Wells Fargo lowered price targets but kept positive ratings. Fourth-quarter net sales reached $5.29 billion, with adjusted EPS of $0.80. The company expects 2026 adjusted EPS of $3.43–$3.49.